The FDA is expected to decide by July 24, 2026, whether to approve a new class of ADHD medication, one that works differently from every other drug currently approved for the condition and would offer a genuine alternative for patients who cannot use or do not respond to stimulants.
The drug is centanafadine, developed by Otsuka Pharmaceutical. It is a once-daily extended-release capsule being reviewed for treatment of attention-deficit hyperactivity disorder in children, adolescents, and adults. The FDA accepted the New Drug Application in January 2026 and granted it Priority Review status — a designation the agency uses for therapies that may offer meaningful advantages over existing treatments.
If approved, centanafadine would be the first drug in a new class called norepinephrine, dopamine, and serotonin reuptake inhibitors, or NDSRIs. No currently approved ADHD medication works by simultaneously blocking the reuptake of all three of those neurotransmitters. That is a clinically meaningful distinction, not marketing language — and it is the reason centanafadine behaves differently from existing options.
Why This Matters
Stimulant medications — primarily amphetamine and methylphenidate products — are the standard first-line treatment for ADHD in both children and adults. For many patients, they work well. But not everyone can use them.
Stimulants are Schedule II controlled substances, carry a risk of dependence and misuse, and are contraindicated or poorly tolerated in patients with certain heart conditions, anxiety disorders, tic disorders, or a history of substance abuse. Stimulant shortages have also created a persistent access problem in the United States. An estimated 15.5 million adults in the United States currently have diagnosed ADHD, according to Otsuka's filing data — and a meaningful percentage of them are either not adequately served by stimulants or actively seeking alternatives.
The current non-stimulant options are limited. Atomoxetine (Strattera) and the alpha-2 agonists guanfacine and clonidine are the primary non-stimulant alternatives. Centanafadine offers a different mechanism entirely — targeting three neurotransmitter systems with a single once-daily dose. If the efficacy and tolerability data hold up to FDA scrutiny, it could meaningfully expand the available options.
John Kraus, MD, PhD, executive vice president and chief medical officer of Otsuka, noted in the company's NDA acceptance announcement that ADHD manifests differently across patients, highlighting the importance of having multiple therapeutic approaches available.
What We Know So Far
The NDA for centanafadine is supported by results from four pivotal Phase 3 clinical trials evaluating efficacy and safety across children, adolescents, and adults. In those trials, centanafadine demonstrated statistically significant and clinically meaningful improvements in ADHD symptoms compared with placebo, as measured by the ADHD Rating Scale-5 in children and adolescents and the ADHD Investigator Symptom Rating Scale in adults.
In children, improvements were documented as early as the first week — a timeline more commonly associated with stimulant medications and meaningfully faster than the several-week onset typical of atomoxetine.
Across all age groups, patients taking the higher dose of centanafadine had significantly fewer ADHD symptoms than those taking placebo. The most common treatment-emergent adverse events reported in clinical trials were decreased appetite, rash, and vomiting — all described as mostly mild or moderate, with low treatment discontinuation rates.
Additionally, Otsuka announced positive Phase 3b results on June 25, 2026, evaluating centanafadine specifically in adults with ADHD and comorbid anxiety — a population that represents up to 50 percent of all adults with ADHD and for whom current treatment options present particular challenges. Centanafadine demonstrated statistically significant and clinically relevant improvements compared to placebo in both ADHD symptoms and anxiety scores, with statistical separation seen as early as week one.
Where the Unmet Need Is Greatest
The patients who stand to benefit most from an approved non-stimulant NDSRI option include some of the most underserved people in ADHD care:
- Adults with ADHD and comorbid anxiety disorders — up to 50 percent of the adult ADHD population — for whom stimulants can worsen anxiety symptoms
- Children whose parents or caregivers prefer a non-Schedule II medication
- Patients with a history of substance use disorder for whom prescribing a controlled stimulant requires additional oversight
- Patients with cardiac conditions or tic disorders for whom stimulants are contraindicated
- Patients in geographic areas experiencing stimulant shortages, which have affected supplies of Adderall and Ritalin since 2022
- Adolescents who are approaching age transitions where access to adult psychiatric care may be limited
The ability of the FDA's approval to cover children, adolescents, and adults in a single label is also notable. Centanafadine is one of the few ADHD drug candidates evaluated across the full age spectrum, making it potentially relevant to family medicine and general practice settings where ADHD management spans multiple life stages.
What Doctors and Experts Say
John Kraus, MD, PhD, chief medical officer of Otsuka, said in the Phase 3b anxiety data announcement that adults with ADHD and comorbid anxiety represent a substantial and particularly challenging population to treat. He said the trial results suggest centanafadine addresses both conditions simultaneously — which no currently approved single drug does.
Patient Care Online noted that the priority review designation shortens the FDA's standard review timeline and signals that the agency considers the application to address an unmet medical need — which is consistent with independent clinical assessments of the non-stimulant ADHD treatment gap.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Four pivotal Phase 3 randomized controlled trials plus one Phase 3b study in ADHD with comorbid anxiety
- Population: Children, adolescents, and adults with ADHD; additional adult cohort with comorbid generalized anxiety disorder or social anxiety disorder
- Submitted to: FDA under NDA with Priority Review, PDUFA date July 24, 2026
- What the trials found: Statistically significant and clinically meaningful improvements in ADHD symptom scores compared with placebo across all age groups; rapid onset in children; improvements in anxiety scores in comorbid anxiety cohort
- Common adverse events: Decreased appetite, rash, vomiting — mostly mild to moderate; low discontinuation rates
- What the trials did not prove: Head-to-head comparison with stimulant medications has not been conducted; long-term data beyond trial duration are not yet available; the FDA has not yet made its decision
- What readers should know: FDA approval is not guaranteed even with strong Phase 3 data; the PDUFA date of July 24 is a decision deadline, not a guaranteed approval date
Who Would Benefit Most?
If centanafadine is approved:
- Children and adolescents with ADHD whose families prefer a non-stimulant option or whose school districts limit access to stimulant dispensing
- Adults with ADHD who have not responded adequately to stimulants or who experience intolerable side effects
- Adults with ADHD and comorbid anxiety, for whom the current treatment landscape requires managing two separate prescriptions with potentially conflicting effects
- Patients in communities with stimulant supply shortages
- Patients with substance use histories who prefer or require a non-scheduled medication
- Older adults with ADHD and cardiovascular comorbidities for whom stimulants carry elevated cardiac risk
Symptoms ADHD Can Cause That Readers May Recognize
ADHD is a neurodevelopmental disorder that presents differently across the lifespan. Common presentations in children include difficulty sustaining attention in school, excessive physical activity, impulsive behavior, poor organizational skills, and difficulty following multi-step instructions.
In adults, ADHD often presents as persistent difficulty with organization, time management, completing tasks, emotional regulation, and maintaining focus during low-stimulation activities. Many adults with ADHD were not diagnosed until well into adulthood — after years of misidentification as anxiety, depression, or a character trait rather than a neurological condition.
Diagnosis of ADHD requires a formal clinical evaluation by a qualified clinician — psychiatrist, psychologist, or trained primary care provider. Do not self-diagnose based on symptom lists or social media content.
What You Can Do Now
- If you or a family member currently has ADHD and is dissatisfied with stimulant treatment, discuss non-stimulant alternatives with your prescribing physician now. Options already available include atomoxetine, guanfacine, and clonidine.
- Monitor the FDA's drug approval announcements page and FDA's new drug approvals page for the July 24 centanafadine decision.
- If approved, ask your clinician whether centanafadine may be appropriate for your specific situation. Approval does not mean it is the right choice for every patient with ADHD.
- If you are struggling to access stimulant medications due to ongoing shortages, contact your state's pharmacy board for information on pharmacies with current supply. The FDA's drug shortage database maintains current information.
- MedicalDaily will publish a same-day update when the FDA issues its centanafadine decision on July 24.
Cost and Access: What Patients Should Know
Existing non-stimulant ADHD medications include generic atomoxetine, which is available at significantly lower cost than brand-name alternatives. If centanafadine is approved, it will initially be a brand-name drug with no generic equivalent, and its cost is expected to be comparable to other branded CNS medications — potentially $300 to $500 or more per month before insurance.
Patients with commercial insurance plans that cover branded ADHD medications are most likely to have access. Medicaid coverage for newly approved branded medications varies by state and formulary cycle. Otsuka typically offers patient assistance programs at launch — patients without adequate coverage should contact Otsuka's patient support team upon approval for program details.
For underinsured patients, NeedyMeds at needymeds.org and the Patient Advocate Foundation provide guidance on accessing medications at reduced or no cost.
What Happens Next
The FDA's decision deadline is July 24, 2026. The agency may approve centanafadine as submitted, approve it with conditions or label modifications, issue a Complete Response Letter requesting additional data, or extend its review. There is no public advisory committee meeting scheduled for this application, which Otsuka has not publicly commented on.
If approved, Otsuka is expected to move quickly toward commercial launch. The company has reported additional ongoing studies in ADHD subpopulations and in other CNS disorders, including work on centanafadine in anxiety-only presentations and in patients with ADHD-associated mood dysregulation.
The Bottom Line
Eleven days from now, the FDA will decide whether to approve the first new class of ADHD medication in many years — one that works differently from every existing option and was specifically tested across children, adolescents, and adults in the same program. For millions of patients who cannot use stimulants or do not respond adequately to them, a July 24 approval would represent a meaningful new option. Whether or not the FDA approves centanafadine on that date, the arrival of a well-powered Phase 3 NDSRI program in ADHD represents a genuine advance in the therapeutic landscape for a condition that affects tens of millions of Americans.
